CY1110915T1 - Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων - Google Patents

Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων

Info

Publication number
CY1110915T1
CY1110915T1 CY20101101030T CY101101030T CY1110915T1 CY 1110915 T1 CY1110915 T1 CY 1110915T1 CY 20101101030 T CY20101101030 T CY 20101101030T CY 101101030 T CY101101030 T CY 101101030T CY 1110915 T1 CY1110915 T1 CY 1110915T1
Authority
CY
Cyprus
Prior art keywords
pml
gene codes
androgen receptors
specific suppression
complementary
Prior art date
Application number
CY20101101030T
Other languages
English (en)
Inventor
Annick Harel-Bellan
Slimane Ait-Si-Ali
Florence Cabon-Georget
Anne Chauchereau
François DAUTRY
Luis Martinez
Original Assignee
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (Cnrs) filed Critical Centre National De La Recherche Scientifique (Cnrs)
Publication of CY1110915T1 publication Critical patent/CY1110915T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Η εφεύρεση αφορά ένα διπλόκλωνο ολιγονουκλεοτίδιο που χαρακτηρίζεται από το ότι συνίσταται από δύο συμπληρωματικές ολιγονουκλεοτιδικές αλληλουχίες που σχηματίζουν ένα υβρίδιο που περιλαμβάνει κάθε μία από αυτές σε ένα από τα 3' ή 5' άκρα αυτής ένα έως πέντε μη-ζευγαρωμένα νουκλεοτίδια που σχηματίζουν μονόκλωνα άκρα αλληλοκαλυπτόμενα από το υβρίδιο, μία δε των εν λόγω ολιγονουκλεοτιδικών αλληλουχιών ουσιαστικά είναι συμπληρωματική μιας αλληλουχίας στόχου που ανήκει σε ένα DNA ή RNA μόριο που θα καταστέλλετε ειδικά. Η εφεύρεση επίσης αφορά την χρήση των εν λόγω ολιγονουκλεοτιδίων στις φαρμακευτικές συνθέσεις κυρίως για την θεραπευτική αγωγή καρκίνων.
CY20101101030T 2001-11-09 2010-11-17 Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων CY1110915T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0114549A FR2832154B1 (fr) 2001-11-09 2001-11-09 Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
FR0204474A FR2838442B1 (fr) 2001-11-09 2002-04-10 Sirnas inhibiteurs de l'expression de genes responsables de l'inactivation de la p53 et leur utilisation dans le traitement des cancers
EP02793219A EP1453962B1 (fr) 2001-11-09 2002-11-08 Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un recepteur aux androgenes

Publications (1)

Publication Number Publication Date
CY1110915T1 true CY1110915T1 (el) 2015-06-10

Family

ID=26213261

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101030T CY1110915T1 (el) 2001-11-09 2010-11-17 Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων

Country Status (12)

Country Link
US (2) US7371735B2 (el)
EP (3) EP1939291B1 (el)
JP (1) JP4323952B2 (el)
AT (1) ATE478143T1 (el)
AU (1) AU2002358881A1 (el)
CA (2) CA2466773C (el)
CY (1) CY1110915T1 (el)
DE (1) DE60237391D1 (el)
DK (1) DK1453962T3 (el)
FR (2) FR2832154B1 (el)
PT (1) PT1453962E (el)
WO (1) WO2003040366A2 (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
EP1438405A1 (de) * 2001-01-09 2004-07-21 Ribopharma AG Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
CN1612930A (zh) * 2001-11-21 2005-05-04 三菱化学株式会社 抑制基因表达的方法
AU2003242688A1 (en) * 2002-06-20 2004-01-06 Dsm Ip Assets B.V. Inhibition of nuclear receptors
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7781575B2 (en) * 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
US7947659B2 (en) * 2004-03-12 2011-05-24 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
CN101277704A (zh) 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
WO2007041497A2 (en) * 2005-09-30 2007-04-12 Cleveland Biolabs, Inc. Modulation of androgen receptor
CA2629564C (en) * 2005-11-15 2014-04-22 Genoid Kft. Method of detecting pathogens
US7740880B2 (en) * 2006-03-03 2010-06-22 University Of Utah Research Foundation Polymeric carrier for delivery of small interfering RNA
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
AR055648A1 (es) * 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
CA2697737A1 (en) * 2007-09-07 2009-03-12 The University Of Tokushima Method for promoting expression of p53, and p53 expression promoter for use in the method
DE102008014318B4 (de) * 2008-03-14 2021-02-04 Premark Feg L.L.C. Transportspülmaschine und Verfahren zum Betreiben einer Transportspülmaschine
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2011005363A2 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
EP2598639A4 (en) 2010-07-28 2014-08-13 Alcon Res Ltd SIRNA TARGETED VEGFA AND IN VIVO TREATMENT PROCESS WITH THIS
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
JP6112569B2 (ja) 2011-12-16 2017-04-12 国立大学法人 東京医科歯科大学 キメラ２重鎖核酸
DK2867368T3 (da) * 2012-07-06 2022-01-31 Roussy Inst Gustave Samtidig detektering af kannibalisme og senescens som prognostisk markør for cancer
WO2014011512A1 (en) 2012-07-08 2014-01-16 Sirnaomics, Inc. Compositions and methods for "resistance-proof" sirna therapeutics for influenza
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
MA40782A (fr) 2014-10-03 2017-08-08 Hocuslocus Llc Procédés et compositions utilisant un arn non codant en vue de la culture et de la sélection de cellules
CN110114076A (zh) * 2016-10-27 2019-08-09 瑟莱塞尔 用于治疗癌症的新型双链寡核苷酸
JP2021514195A (ja) * 2018-02-21 2021-06-10 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
EP3946629A4 (en) * 2019-03-26 2023-04-05 University Of Massachusetts THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
EP0684764A4 (en) * 1993-02-19 1997-10-22 Genta Inc TREATMENT OF ANDROGEN-RELATED COALNESS BY USING ANTISENSE OLIGOMERS.
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
AU7983294A (en) 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
US5556956A (en) * 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
WO1996000286A1 (fr) * 1994-06-27 1996-01-04 Toagosei Co., Ltd. Compose d'acide nucleique antisens
AU4961996A (en) * 1994-12-14 1996-07-03 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
AU767662B2 (en) * 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
EP0978561A1 (en) 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
CA2347905C (en) 1998-10-26 2009-12-15 Avi Biopharma, Inc. P53 antisense agent and method
BR0009884A (pt) * 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
GB9910119D0 (en) 1999-04-30 1999-06-30 Novartis Ag Organic compounds
JP4638098B2 (ja) 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
AU2925401A (en) 2000-01-19 2001-07-31 Parkash S Gill Methods and compositions for antisense vegf oligonucleotides
ATE450621T2 (de) * 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2448320A1 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
US20040235171A1 (en) 2001-07-17 2004-11-25 Milner Ann Josephine Silencing of gene expression by sirna
JP2005517452A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＢＣＬ２遺伝子発現のＲＮＡ干渉媒介性阻害
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004022777A1 (en) 2002-09-04 2004-03-18 Johnson & Johnson Research Pty Ltd METHODS USING dsDNA TO MEDIATE RNA INTERFERENCE (RNAi)
NZ540779A (en) 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
US7947659B2 (en) * 2004-03-12 2011-05-24 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101397407B1 (ko) * 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
WO2010105209A1 (en) * 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
WO2011017548A1 (en) 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2011034798A1 (en) 2009-09-15 2011-03-24 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes

Also Published As

Publication number Publication date
AU2002358881A1 (en) 2003-05-19
CA2789407C (fr) 2017-10-31
FR2838442B1 (fr) 2007-06-08
PT1453962E (pt) 2010-11-29
EP3037537A1 (fr) 2016-06-29
EP1939291B1 (fr) 2016-08-17
EP1939291A2 (fr) 2008-07-02
US7371735B2 (en) 2008-05-13
US8318689B2 (en) 2012-11-27
EP1453962A2 (fr) 2004-09-08
WO2003040366A3 (fr) 2004-07-01
CA2466773A1 (fr) 2003-05-15
FR2832154B1 (fr) 2007-03-16
ATE478143T1 (de) 2010-09-15
US20080287385A1 (en) 2008-11-20
DE60237391D1 (de) 2010-09-30
FR2838442A1 (fr) 2003-10-17
CA2466773C (fr) 2012-10-16
FR2832154A1 (fr) 2003-05-16
WO2003040366A2 (fr) 2003-05-15
DK1453962T3 (da) 2010-12-20
JP2005508188A (ja) 2005-03-31
US20050215497A1 (en) 2005-09-29
EP1939291A3 (fr) 2012-02-22
JP4323952B2 (ja) 2009-09-02
CA2789407A1 (fr) 2003-05-15
EP1453962B1 (fr) 2010-08-18

Similar Documents

Publication Publication Date Title
CY1110915T1 (el) Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων
Arzumanov et al. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2 ‘-O-methyl/LNA oligoribonucleotides
Fabani et al. miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates
EP2363479B1 (de) Oligoribonukleotid zur Hemmung der Expression eines vorgegebenen Gens
US5849902A (en) Three component chimeric antisense oligonucleotides
US20030083477A1 (en) Three component chimeric antisense oligonucleotides
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
JP2015523853A5 (el)
CA2385853A1 (en) Design of high affinity rnase h recruiting oligonucleotide
JP2002510207A (ja) 拡張された開裂ルールを有するハンマーヘッドリボザイム
JP2015519057A5 (el)
RU2010120715A (ru) Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции
EP0968226A1 (en) G-rich oligo aptamers and methods of modulating an immune response
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
Holmes et al. Steric inhibition of human immunodeficiency virus type‐1 Tat‐dependent trans‐activation in vitro and in cells by oligonucleotides containing 2′‐O‐methyl G‐clamp ribonucleoside analogues
JP2007530431A5 (el)
Williamson G-quartets in biology: reprise.
JP6882735B2 (ja) 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ
Abe et al. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides
CA3216819A1 (en) Gene expression regulatory system using crispr system
DE60110244D1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide
JP2009504190A5 (el)
IL159759A (en) History of oligoribonucleotide for deliberate inhibition of gene expression, medicinal preparations containing them, methods for their preparation and use
AU2001258274A1 (en) Synthetic oligonucleotides as inducers of erythroid differentiation